← Leaderboards
Yupo Ma
University Of Arkansas Med Scis Ltl Rock
$4,289,154
Attributed
$4,289,154
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $954.4K · FY2005–12$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$4,289,154 · 6
By mechanism
R01$2,666,017 · 1
K08$648,563 · 1
P20$553,674 · 3
R21$420,900 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cell Line”
- David Heimbrook · Leidos Biomedical Research, Inc.$236,973,333
- Dennis R. Burton · Scripps Research Institute$203,685,614
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$177,001,772
- John M Lachin · George Washington University$118,672,444
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- Fred M Gordin · Social And Scientific Systems, Inc.$82,802,056
Research focus
Cell LineMutationProtein IsoformsExhibitsLeukemia, Myelocytic, AcuteCellsLeukemiaMolecularOncogenesDrosophila GenusBasePathway InteractionsGenesMalignant NeoplasmsPlayDysmyelopoietic SyndromesAmericanHematopoietic Stem CellsInnovationGeneticBritishIncidenceIn VivoElderly
Grant awards (21)
A model of myelodysplastic syndrome progression and leukemic stem cells$413,624
R01 · FY2012 · HL · contact PI
A model of myelodysplastic syndrome progression and leukemic stem cells$508,586
R01 · FY2011 · HL · contact PI
A model of myelodysplastic syndrome progression and leukemic stem cells$506,639
R01 · FY2010 · HL · contact PI
A model of myelodysplastic syndrome progression and leukemic stem cells$44,161
R01 · FY2010 · HL · contact PI
A mouse model of myelodysplastic syndrome progression and leukemic stem cells$7,041
R01 · FY2010 · HL · contact PI
A mouse model of myelodysplastic syndrome progression and leukemic stem cells$450,000
R01 · FY2009 · HL · contact PI
A mouse model of myelodysplastic syndrome progression and leukemic stem cells$198,581
R01 · FY2009 · HL · contact PI
Flexible and Somatic Mouse Models for Myelodysplastic Syndrome Progression$159,905
R21 · FY2009 · CA · contact PI
A mouse model of myelodysplastic syndrome progression and leukemic stem cells$60,835
R01 · FY2009 · HL · contact PI
Flexible and Somatic Mouse Models for Myelodysplastic Syndrome Progression$58,495
R21 · FY2009 · CA · contact PI
A mouse model of myelodysplastic syndrome progression and leukemic stem cells$26,550
R01 · FY2009 · HL · contact PI
A mouse model of myelodysplastic syndrome progression and leukemic stem cells$450,000
R01 · FY2008 · HL · contact PI
Flexible and Somatic Mouse Models for Myelodysplastic Syndrome Progression$202,500
R21 · FY2008 · CA · contact PI
FUNCTIONAL ANALYSIS OF SALL4$182,980
P20 · FY2008 · RR · contact PI
TARGET FACULTY MA/FUNCTIONAL ANALYSIS OF SALL4$182,569
P20 · FY2007 · RR · contact PI
Role of Hsal 2 in Ovarian Cancer$113,963
K08 · FY2007 · CA · contact PI
TARGET FACULTY RESEARCH/FUNCTIONAL ANALYSIS OF SALL4$188,125
P20 · FY2006 · RR · contact PI
Role of Hsal 2 in Ovarian Cancer$133,650
K08 · FY2006 · CA · contact PI
Role of Hsal 2 in Ovarian Cancer$133,650
K08 · FY2005 · CA
Role of Hsal 2 in Ovarian Cancer$133,650
K08 · FY2004 · CA
Role of Hsal 2 in Ovarian Cancer$133,650
K08 · FY2003 · CA